APOE and Alzheimer disease: Thus, we explored the APOE4 effects using the iPSC-derived cerebral organoids from an AD patient carrying APOE ε4/ε4 (APOE4) and the corresponding APOE ε3/ε3 (APOE3) isogenic line at Day 90.